Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit
Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. Learn how you can help make a difference by joining the All of Us Research Program.
Displaying 51 - 60 of 261
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)
Protocol No
ECOG-EA8212-BRIDGE
Categories
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refr
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR-T Cells in Adults with rr LBCL
Protocol No
ALLOGENE-ALLO-501A-201
Categories
Effects of Transcranial Direct Current Stimulation (tDCS) on Language
Effects of Transcranial Direct Current Stimulation (tDCS) on Language
Protocol No
NEURO-AHW-TDCS-LANGUAGE
Categories
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Ma
Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
Protocol No
ADP-0000-001-SCR
Categories
Cancer,
Gynecologic Cancers,
Prostate and Urologic Cancers,
Other Respiratory,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Ovary,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Head and Neck Cancers,
Gastrointestinal Cancers,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus,
Colorectal
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Compl
Rituximab with or without SCT in Treating Pt with MRD-Neg MCL in First Complete Remission
Protocol No
ECOG-EA4151
Categories
A Dose Escalation and Expansion Study of AbbVie's Compound in Combination with Anti-Cancer Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
A Study of Abbvie M22-947 in Patients with Relapsed Refractory Multiple Myeloma
Protocol No
ABBVIE-M22-947
Categories
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory MM
Protocol No
IIT-DHAKAL-IMPEDE-SGZ-12356
Categories
Combination Post-transplant Consolidation Therapy with Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients with Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)
The purpose of this study is to test the safety and effectiveness of the new study drug combination of Isatuximab, Lenalidomide, and Dexamethasone for the treatment of multiple myeloma in patients with Persistent Marrow Minimal Residual Disease.
Protocol No
IIT-MOHAN-E-MAT
Categories
Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs
PRIME-Prematurity Risk Assessment With Clinical Interventions for Improving Neonatal outcoMEs
Protocol No
OBG-SERA-PRIME
Categories
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination with Dexamethasone and Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and t(11;1
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Protocol No
BEIGENE-BGB-11417-105